PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aravive Biologics and WuXi Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500
Aravive Biologics, Inc. and WuXi Biologics (WuXi Bio, 02269.HK) today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive’s lead drug candidate, AVB-S6-500 (previously
View HTML